Susan Keefe - 02 Feb 2022 Form 4 Insider Report for GreenLight Biosciences Holdings, PBC

Role
CFO & Interim CAO
Signature
/s/ David Kennedy, Attorney-in-fact
Issuer symbol
N/A
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 19:01:51 UTC
Next filing
08 Aug 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRNA Stock Option (Right to Buy) Award +488,466 488,466 02 Feb 2022 Common Stock 488,466 $0.5000 Direct F1, F2
transaction GRNA Stock Option (Right to Buy) Award +565,760 565,760 02 Feb 2022 Common Stock 565,760 $0.9800 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 20% of the shares underlying the option vested or shall vest on June 3, 2020 and the remainder of the shares vested or shall vest in 48 equal monthly installments thereafter, starting July 3, 2020.
F2 This option was issued pursuant to the terms of a business combination agreement involving the Issuer and GreenLight Biosciences, Inc. in exchange for a comparable option previously issued by such company.
F3 25% of the shares underlying the option vested or shall vest on December 1, 2021 and the remainder of the shares vested or shall vest in 36 equal monthly installments thereafter, starting January 1, 2022.